ReviewClinics (Sao Paulo, Brazil)2015
Cytomegalovirus infection in transplant recipients.
Review in Clinics (Sao Paulo, Brazil), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
143 citing papers in PubMed, 2 syntheses or guidelines pooled it, 322 citations in OpenAlex.
- Secondary anti-viral prophylaxis in solid organ transplant recipients for the prevention of cytomegalovirus relapse: A systematic review and meta-analysis.Transplant infectious disease : an official journal of the Transplantation Society · 2024Pooled it
- Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature.Transplant infectious disease : an official journal of the Transplantation Society · 2020Pooled it
- Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open-Label, Single-Dose, Parallel Group Study.Journal of clinical pharmacology · 2023Trial
- Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019Trial
- CAR T cell therapy beyond cancer: current status, challenges and future prospects.Signal transduction and targeted therapy · 2026Review
- Mechanisms and Determinants of CMV Reactivation in Kidney Transplantation.International journal of molecular sciences · 2026Review
- Maribavir for cytomegalovirus retinitis: A case series and review of the literature.AJO international · 2026Article
- Incidence and risk factors of cytomegalovirus infection in solid organ transplant recipients: a nationwide Korean study.Clinical transplantation and research · 2026Article
- Severe hemorrhage of the colorectum after heart transplantation: a case report.World journal of emergency medicine · 2026Article
- Immunomodulatory Strategies for Managing Viral Infections in Solid Organ Transplantation: Progress and Challenges.Current microbiology · 2026Review
- Diabetes Mellitus is a Risk Factor for Developing CMV Retinitis in Solid Organ Transplant Recipients: A Case-control Study.Open forum infectious diseases · 2026Article
- Detection of Cytomegalovirus in Patients Attending a Tertiary Care Center: A Retrospective Analysis.Cureus · 2026Article
- Molecular characterization of cytomegalovirus based on glycoprotein B and N among solid organ and hematopoietic stem cell transplant recipients in Jordan.Iranian journal of microbiology · 2026Article
- CMV prevention in heart transplant recipients: Comparative analysis of preemptive and prophylactic strategies.Turk gogus kalp damar cerrahisi dergisi · 2026Article
- A comprehensive method for quantifying human cytomegalovirus plaque assays.Frontiers in cellular and infection microbiology · 2026Article
- Living Donor Intestinal Transplant: Indication, Techniques, Surgical Complications, and Outcomes in Recipients and Donors: A Systematic Review.Journal of transplantation · 2026Review
- Third annual transplant AI symposium: from organ matching to digital twins.Frontiers in transplantation · 2026Article
- Boosting the Predictive Power of Virus-Specific T-Cell Clinical Trials via Generative Models.Computational and structural biotechnology journal · 2026Article
- Palmitoylation of the human cytomegalovirus tegument protein pp28 facilitates virus release.PLoS pathogens · 2026Article
83 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus infection is a frequent complication after transplantation. This infection occurs due to transmission from the transplanted organ, due to reactivation of latent infection, or after a primary infection in seronegative patients and can be defined as follows: latent infection, active infection, viral syndrome or invasive disease. This condition occurs mainly between 30 and 90 days after transplantation. In hematopoietic stem cell transplantation in particular, infection usually occurs within the first 30 days after transplantation and in the presence of graft-versus-host disease. The major risk factors are when the recipient is cytomegalovirus seronegative and the donor is seropositive as well as when lymphocyte-depleting antibodies are used. There are two methods for the diagnosis of cytomegalovirus infection: the pp65 antigenemia assay and polymerase chain reaction. Serology has no value for the diagnosis of active disease, whereas histology of the affected tissue and bronchoalveolar lavage analysis are useful in the diagnosis of invasive disease. Cytomegalovirus disease can be prevented by prophylaxis (the administration of antiviral drugs to all or to a subgroup of patients who are at higher risk of viral replication) or by preemptive therapy (the early diagnosis of viral replication before development of the disease and prescription of antiviral treatment to prevent the appearance of clinical disease). The drug used is intravenous or oral ganciclovir; oral valganciclovir; or, less frequently, valacyclovir. Prophylaxis should continue for 90 to 180 days. Treatment is always indicated in cytomegalovirus disease, and the gold-standard drug is intravenous ganciclovir. Treatment should be given for 2 to 3 weeks and should be continued for an additional 7 days after the first negative result for viremia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.